Corvus Pharmaceuticals Expands Equity Sales Capacity to $200 Million

Corvus Pharmaceuticals ( (CRVS) ) just unveiled an update.

On March 13, 2026, Corvus Pharmaceuticals amended and restated its open market sale agreement with Jefferies LLC, expanding the maximum aggregate amount of common stock it may sell from $100 million to $200 million, after having sold no shares under the prior 2024 agreement. The company also filed an automatically effective shelf registration and related prospectus supplement on March 13, 2026, enabling flexible, at-the-market and other legally permitted equity sales, with Jefferies earning up to a 3% commission and receiving customary indemnification, which collectively bolster Corvus’s capacity to raise capital as needed.

Sales under the amended agreement may occur through at-the-market offerings, block trades, or privately negotiated transactions, providing Corvus with multiple channels to tap public equity markets. The structure of the agreement and associated legal opinions underscore a standard capital-raising framework that could support the company’s future funding needs while signaling to investors a readiness to access up to $200 million in incremental equity financing.

The most recent analyst rating on (CRVS) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Corvus Pharmaceuticals stock, see the CRVS Stock Forecast page.

Spark’s Take on CRVS Stock

According to Spark, TipRanks’ AI Analyst, CRVS is a Neutral.

The score is held back primarily by weak financial performance (pre-revenue losses and ongoing cash burn) and limited support from conventional valuation metrics (negative P/E, no dividend). These are partially offset by a strong earnings-call backdrop (promising clinical signals and a substantially extended cash runway) and a mixed but still longer-term constructive technical trend.

To see Spark’s full report on CRVS stock, click here.

More about Corvus Pharmaceuticals

Corvus Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative pharmaceutical products. The company accesses the capital markets to support its operations and potential pipeline advancement through equity offerings of its common stock.

Average Trading Volume: 3,552,993

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.34B

See more insights into CRVS stock on TipRanks’ Stock Analysis page.